# A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

> **NCT03856411** · PHASE3 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 465 (actual)

## Conditions studied

- Treatment-naive Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

## Key facts

- **NCT ID:** NCT03856411
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2022-08-31
- **Final completion:** 2023-01-09
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856411, "A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03856411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*